Menu
Back to Journals » Drug, Healthcare and Patient Safety » Volume 2
Drug, Healthcare and Patient Safety
ISSN: 1179-1365
- View all (278)
- Volume 15, 2023 (16)
- Volume 14, 2022 (19)
- Volume 13, 2021 (25)
- Volume 12, 2020 (35)
- Volume 11, 2019 (15)
- Volume 10, 2018 (12)
- Volume 9, 2017 (11)
- Volume 8, 2016 (13)
- Volume 7, 2015 (20)
- Volume 6, 2014 (22)
- Volume 5, 2013 (23)
- Volume 4, 2012 (18)
- Volume 3, 2011 (15)
- Volume 2, 2010 (25)
- Volume 1, 2009 (9)
Archive: Volume 2, 2010
TNF-α inhibitors: are they carcinogenic?
αGirindra Raval, Paulette Mehta
Drug, Healthcare and Patient Safety 2010, 2:241-247
Published Date: 6 December 2010
Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
Paul A Gurbel, Udaya S Tantry, Dean J Kereiakes
Drug, Healthcare and Patient Safety 2010, 2:233-240
Published Date: 15 November 2010
Insomnia medication use and the probability of an accidental event in an older adult population
Alon Y Avidan, Liisa A Palmer, Justin F Doan, et al
Drug, Healthcare and Patient Safety 2010, 2:225-232
Published Date: 12 November 2010
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
Kitty Poon, Allen B King
Drug, Healthcare and Patient Safety 2010, 2:213-223
Published Date: 28 October 2010
Safety and tolerability of antipsychotics: focus on amisulpride
Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira
Drug, Healthcare and Patient Safety 2010, 2:205-211
Published Date: 1 October 2010
Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
Harald Vonkeman, Inger Meek, Mart van de Laar
Drug, Healthcare and Patient Safety 2010, 2:191-204
Published Date: 6 October 2010
Antiepileptic drugs and suicidality
Jeffery W Britton, Jerry J Shih
Drug, Healthcare and Patient Safety 2010, 2:181-189
Published Date: 28 September 2010
Safety and clinical efficacy of golimumab in the treatment of arthritides
Ismail Simsek, Yusuf Yazici
Drug, Healthcare and Patient Safety 2010, 2:169-180
Published Date: 28 September 2010
Profound thrombocytopenia after primary exposure to eptifibatide
Nicholas B Norgard, Brian T Badgley
Drug, Healthcare and Patient Safety 2010, 2:163-167
Published Date: 21 September 2010
Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy
Mitchell S Buckley, Robin L Staib, Laura M Wicks, et al
Drug, Healthcare and Patient Safety 2010, 2:151-161
Published Date: 20 September 2010
Antidepressant-associated sexual dysfunction: impact, effects, and treatment
Agnes Higgins, Michael Nash, Aileen M Lynch
Drug, Healthcare and Patient Safety 2010, 2:141-150
Published Date: 9 September 2010
A danger of induction of Brugada syndrome during pill-in-the-pocket therapy for paroxysmal atrial fibrillation
Yoshiyasu Aizawa, Tomohiro Matsuhashi, Toshiaki Sato, et al
Drug, Healthcare and Patient Safety 2010, 2:139-140
Published Date: 25 August 2010
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
Luca Dalle Carbonare, Mirko Zanatta, Adriano Gasparetto, et al
Drug, Healthcare and Patient Safety 2010, 2:121-137
Published Date: 19 August 2010
Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations
Sarah Horton, Maya H Buch, Paul Emery
Drug, Healthcare and Patient Safety 2010, 2:101-119
Published Date: 17 August 2010
Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital
Rajakannan Thiyagu, Surulivel R Mallayasamy, Valakkathala Rajesh, et al
Drug, Healthcare and Patient Safety 2010, 2:95-100
Published Date: 30 June 2010
Incorrect description of mode of excretion of linagliptin
Hans-Juergen Woerle, Sanjay Patel
Drug, Healthcare and Patient Safety 2010, 2:93-94
Published Date: 2 June 2010
Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
Rohan Shahani, Kevin G Kwan, Anil Kapoor
Drug, Healthcare and Patient Safety 2010, 2:85-91
Published Date: 28 June 2010
Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension
Parul Ichhpujani, L Jay Katz
Drug, Healthcare and Patient Safety 2010, 2:73-83
Published Date: 24 May 2010
Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
Adie Viljoen, Anthony S Wierzbicki
Drug, Healthcare and Patient Safety 2010, 2:61-71
Published Date: 24 May 2010
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options
Juraj Payer, Kristina Brazdilova, Peter Jackuliak
Drug, Healthcare and Patient Safety 2010, 2:49-59
Published Date: 20 May 2010
Preclinical pharmacology, efficacy, and safety of varenicline in smoking cessation and clinical utility in high risk patients
Zheng-Xiong Xi
Drug, Healthcare and Patient Safety 2010, 2:39-48
Published Date: 14 April 2010
Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections
Dionissios Neofytos, Edina Avdic, Anna-Pelagia Magiorakos
Drug, Healthcare and Patient Safety 2010, 2:27-38
Published Date: 20 April 2010
Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers
Elisabet Ekman, Staffan Hägg, Anders Sundström, et al
Drug, Healthcare and Patient Safety 2010, 2:21-25
Published Date: 29 March 2010
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
Mary Elizabeth Cox, Jennifer Rowell, Leonor Corsino, et al
Drug, Healthcare and Patient Safety 2010, 2:7-19
Published Date: 28 January 2010
Beyond the black box: drug- and device-associated hypersensitivity events
Charles L Bennett, Olatokunbo S Adegboro, Elizabeth A Calhoun, Dennis Raisch
Drug, Healthcare and Patient Safety 2010, 2:1-5
Published Date: 16 February 2010